What Is Pancragen? The KEDW Pancreas Peptide Bioregulator
Pancragen (KEDW / Lys-Glu-Asp-Trp) is a synthetic Khavinson 'Cytogen' peptide linked to the pancreas. What the single-lineage lab evidence actually shows.
Pancragen is the trade name for the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW), a Khavinson 'Cytogen' bioregulator associated with the pancreas. In cell cultures and rodent diabetes models it is reported to influence insulin-related gene expression and islet cell differentiation. The evidence is a small, single-lineage body of Russian gerontology research.
Pancragen is one of the shortest entries in the Khavinson catalogue of tissue-specific peptides: four amino acids, Lys-Glu-Asp-Trp, nominally directed at the pancreas. It sits beside Cardiogen for the heart and Livagen for the liver in a program that has run for two decades out of a single St. Petersburg institute. The chemistry is unambiguous; the biology is a small, single-lineage body of Russian gerontology research whose claims have never been reproduced independently in the West. Everything below describes laboratory and literature findings, not use in people.
What is Pancragen, structurally?
Pancragen is the trade name for the synthetic tetrapeptide Lys-Glu-Asp-Trp, abbreviated KEDW in single-letter code. The form that actually appears in the reproducible chemical databases is the C-terminally amidated variant, H-Lys-Glu-Asp-Trp-NH2 (KEDWa), which resolves to PubChem CID 68451868 with molecular formula C26H37N7O8 and a molecular weight near 575.6 g/mol. The amidation is not cosmetic: capping the C-terminus removes a free carboxylate and is one of the standard tricks for slowing exopeptidase cleavage of a short peptide. The plain free-acid « Lys-Glu-Asp-Trp » does not map to a clean PubChem or CAS record under ordinary names, so the amidated peptide is the correct reference identifier to use when sourcing or characterising the compound.
The design rationale, as stated in the origin paper, is that KEDWa mimics a conserved four-residue fragment shared by insulinotropic polypeptides, engineered as a protease-protected analog so that the motif survives long enough to act.1 That single sentence explains both the naming and the whole line of inquiry: the peptide was built to look like a piece of an insulin-related signalling molecule, and every downstream study asks whether it behaves like one.
575.6 the approximate molecular weight, in g/mol, of the amidated KEDWa form (PubChem CID 68451868) — the reproducible chemical identity behind the « Pancragen » name.
What does the pancreas literature actually report?
The rodent work is where the pancreas association was first built. In alloxan-diabetic rats, the tetrapeptide was reported to partially restore insulin synthesis, and the authors proposed a specific mechanism: activation of the preproinsulin gene promoter through binding at ggcagg/cctgcc sequences.1 A companion streptozotocin-diabetes study named the peptide as pancragen (Lys-Glu-Asp-Trp-NH2) and reported that oral administration produced a hypoglycemic effect while intramuscular administration normalized mesenteric capillary endothelial adhesion.2 A separate histomorphology paper described a regulatory effect on pancreatic tissue structure in diabetic rats, supplying the tissue-level correlate to the biochemistry.3 A later survey of KEDW-NH2 activity spanned ontogeny and the streptozotocin rapid-aging model, framing the peptide as an endogenous regulator rather than a foreign drug.4
The flagship in-vivo data are two companion studies in aged rhesus monkeys. The first examined Pancragen’s effect on endocrine pancreatic function in old female Macaca mulatta, positioning it as a correction of age-related islet dysfunction.5 The second is the study most people mean when they cite « the monkey data »: nine old (20–25 year) female monkeys, five given Pancragen at 0.05 mg per animal per day intramuscularly for ten days, compared against four on the standard hypoglycemic drug glimepiride.6 That 0.05 mg per animal figure is an animal-study parameter reported by the investigators, not a protocol directed at any reader.
| Research strand | What was observed | System |
|---|---|---|
| Islet differentiation | Upregulation of Pdx1, Ptf1a, Pax6, Pax4, Foxa2, Nkx2.2 | Pancreatic cell culture, young and aged7 |
| Functional cell activity | Increased MMP2/MMP9, serotonin, CD79α, Mcl1, PCNA/Ki67; decreased p53 | Aged human pancreatic cell culture8 |
| Tissue specificity | Stimulation of CXCL12, Hoxa3 in pancreatic cells, distinct from other Cytogens | Comparative cell culture9 |
| Chromatin/DNA binding | Histone binding; in-silico groove binding at a GGCAG site | Biochemical binding + molecular modelling10,11 |
| Epigenetic | Shifts in DNA methylation of PDX1, PAX6, NGN3, NKX2-1 promoters | Aging human cell culture12 |
All entries are in-vitro, in-silico, or animal findings from the originating research lineage. None represents demonstrated clinical benefit in humans.
The peptide was built to look like a fragment of an insulinotropic molecule — and every study since has asked whether looking like one is enough to act like one.
The proposed mechanism, and how far it is actually demonstrated
Three mechanistic strands run through the Pancragen literature, and it helps to keep them separate because they carry different evidential weight. The first is differentiation: in pancreatic cell cultures the peptide was reported to raise the pancreatic transcription factors that define islet cell fate — Pdx1, Ptf1a, Pax6, Pax4, Foxa2, Nkx2.2 — in both young and aged cultures, offered as the basis for an anti-diabetic effect.7 A functional-activity study in aged human pancreatic cultures reported a broad shift toward a « younger » phenotype: increased MMP2/MMP9, serotonin, CD79α, anti-apoptotic Mcl1, and the proliferation markers PCNA and Ki67, with decreased pro-apoptotic p53.8 A tissue-specificity paper reported that Pancragen raised CXCL12 and Hoxa3 in pancreatic cells specifically, distinct from what related peptides did in other tissues.9
The second strand is direct chromatin interaction. Short peptides including Lys-Glu-Asp-Trp were shown to bind wheat core histones at their N-terminal regions in a FITC-labelled binding assay — genuine biochemical evidence that the KEDW family physically associates with chromatin proteins.10 The third strand is epigenetic: KEDW was reported to alter gene expression tissue-specifically and to shift DNA-methylation patterns at the PDX1, PAX6, NGN3, and NKX2-1 promoters in aging cultures.12 A molecular-mechanics modelling study proposed that the peptide can occupy both the minor and major DNA grooves, nominating GGCAG as a putative binding site.11 An indexed English-language review places KEDW within this differentiation program, pairing it with AEDL for lung as the pancreatic member.13
Read carefully, the chain runs from a computational binding hypothesis to correlational changes in gene expression to observed cell-culture phenotypes. Each link is published; none is a direct causal demonstration in a living pancreas that the peptide binds GGCAG and thereby drives preproinsulin transcription in vivo. The modelling shows plausibility, not proof.
An honest read of the evidence
The single most important fact about Pancragen is provenance. Essentially every primary paper traces back to Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology and a tight circle of collaborators — Goncharova, Linkova, Kvetnoy, Tarnovskaya, Vanyushin. There is no independent Western group that has reproduced the pancreas or insulin claims. A body of work confined to one lineage is a hypothesis with a lot of internal detail, not an established result, and the pancreas-insulin story should be read that way.
The numbers are small and the systems are mostly not human. The flagship glucose-tolerance study rested on five Pancragen animals.6 Much of the mechanism is cell culture or purely in-silico molecular modelling,11 which establishes that a mechanism is chemically conceivable, not that it operates. The DNA-groove-binding and promoter-activation claims in particular are hypotheses supported by modelling and correlational expression data, not by causal demonstration in vivo.
On human data, precision matters. It is not accurate to say there is none: a small observational report examined pancragen for metabolic correction in elderly subjects (30 healthy plus 33 type-2 diabetics) and described lowered fasting and OGTT glucose, insulin, and insulin-resistance index.14 But that is open-label, tiny-n, and from the same lineage — there are no independent, controlled human trials, only small open-label reports from the originating group. It undercuts a strict « no human data whatsoever » claim without coming close to establishing clinical efficacy. The publication venues compound the problem: predominantly Russian-language gerontology journals such as Advances in Gerontology and the Bulletin of Experimental Biology and Medicine, with terse abstracts and limited external scrutiny or translation. Finally, a nomenclature caution worth repeating: the free-acid « Lys-Glu-Asp-Trp » does not resolve to a clean PubChem or CAS entry; only the amidated KEDWa (CID 68451868) does. Anyone treating the plain and amidated forms as interchangeable is glossing over a real chemical distinction. Readers curious about how the rest of this family holds up under the same lens can compare our companion pieces on Livagen and Vilon, the broader Khavinson bioregulator overview, and the practical tissue-by-peptide map.
All materials supplied by Condor Research are Research Use Only (RUO). Everything above is drawn from in-vitro, in-silico, animal, and small observational literature; none of it is a dosing protocol, clinical guidance, or a safety assessment for any organism. KEDW/Pancragen holds no marketing authorisation as a medicine in the EU, UK, or US, and nothing here should be read as directing its use in humans or animals.
Condor Research · Service scientifique
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW); the studied, reproducible form is the C-terminally amidated H-Lys-Glu-Asp-Trp-NH2 (KEDWa), which resolves to PubChem CID 68451868, formula C26H37N7O8, MW ~575.6 g/mol.
- It was designed as a protease-resistant analog of a conserved four-residue fragment shared by insulinotropic polypeptides, framing it as a pancreas-directed member of the Cytogen family alongside Livagen and Cardiogen.
- The literature spans three strands from one lineage: islet-cell differentiation factors (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2, Ptf1a), chromatin/DNA binding (histones; in-silico groove binding at a GGCAG site), and DNA-methylation shifts at PDX1/PAX6/NGN3/NKX2-1 promoters.
- The flagship in-vivo data are two companion aged-rhesus-monkey studies; the glucose-tolerance study used only 5 Pancragen animals dosed at 0.05 mg/animal/day IM for 10 days versus 4 on glimepiride.
- Rodent alloxan/streptozotocin diabetes models report partial restoration of insulin synthesis, lowered blood glucose, and normalized mesenteric capillary endothelial adhesion.
- There is no independent Western replication and no rigorous randomized controlled trial; the only human data are small, open-label reports from the originating St. Petersburg group.
- KEDW/Pancragen is not an approved medicine in the EU, UK, or US and holds no marketing authorisation; it is treated here strictly as a synthetic reference peptide for laboratory research.
What is Pancragen made of?
Pancragen is the tetrapeptide Lys-Glu-Asp-Trp (KEDW). The form used in the reproducible chemical databases is the amidated H-Lys-Glu-Asp-Trp-NH2 (KEDWa): PubChem CID 68451868, formula C26H37N7O8, molecular weight approximately 575.6 g/mol. It was designed as a protease-resistant analog of a conserved fragment of insulinotropic polypeptides.
Why is it associated with the pancreas?
Because it was engineered to mimic a fragment shared by insulinotropic polypeptides, and its animal and cell-culture literature centres on insulin synthesis, glucose handling, and islet-cell differentiation factors. The association is a research framing built by one lineage, not a proven physiological role.
What did the monkey study actually do?
Two companion studies in aged female rhesus monkeys examined Pancragen on pancreatic endocrine function. In the glucose-tolerance study, nine old monkeys were split into five receiving Pancragen at 0.05 mg per animal per day intramuscularly for ten days and four receiving glimepiride, a standard hypoglycemic drug, for comparison. The Pancragen group was five animals — a very small sample.
Is there any human evidence?
Only a small open-label observational report from the originating group, covering 30 healthy elderly subjects and 33 with type-2 diabetes, which described reductions in glucose, insulin, and an insulin-resistance index. It is not a controlled clinical trial and does not establish efficacy.
How does Pancragen relate to Livagen and Vilon?
They are all short peptides from the same Cytogen program and the same laboratory, each nominally assigned to a tissue — Pancragen to the pancreas. The overarching claim of the program is "tissue specificity," reported for Pancragen in comparative cell-culture work. The same single-lineage caveat applies across the family.
Is Pancragen an approved treatment?
No. It has no marketing authorisation as a medicine in the EU, UK, or US and is handled strictly as a synthetic research peptide. The published findings are laboratory and small observational data, not a basis for use in people or animals.